Enterprise record

ASCENTAGE PHARMA GROUP INTERNATIONAL logo

ASCENTAGE PHARMA GROUP INTERNATIONAL

Based in Suzhou, China, Ascentage Pharma Group International is a biotechnology firm primarily focused on clinical-stage development. The company is dedicated to discovering and advancing therapeutic solutions for a range of medical conditions, including various cancers, chronic hepatitis B virus (HBV) infections, and age-related ailments. A cornerstone of its product pipeline is HQP1351, a BCR-ABL inhibitor specifically designed to address BCR-ABL1 mutants, notably those carrying the T315I muta

Follow
More
Reports & analysis (Directory temporarily unavailable)Alpha EvalSave PDFCompareChallenge a ClaimClaim this record

Alpha ID: alpha:company:06c6c502-59c7-4d92-bd02-81b970584888Version: public-1As of: unavailable

18 published Claims2 sources

Key Claims

Board and committees

Source-backed public-market identity

Index memberships

Current memberships are attached to a specific security and listing. Announcements, effective dates, and removals remain distinct states; Alpha does not infer membership from company size, exchange, or reputation.

No current membership is published in Alpha's tracked index universe.

This is not evidence that the company is absent from every market index.

As of Sep 30, 2026. Rights-filtered public evidence only; no redistribution or model training is granted.

Only source-backed memberships with an explicit public redistribution basis are returned.

Evidence, history and coverage

Additional published Claims

Published evidence records

2 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. Alpha canonical company public projection

    canonical identity · Source published: Date unavailable · Retrieved: Sep 30, 2026

    Supports 5 claims
    • Legal Name: ASCENTAGE PHARMA GROUP INTERNATIONAL · Claim reviewed: Sep 30, 2026
    • Entity Status: Public listing published · Claim reviewed: Sep 30, 2026
    • Published Fact: US · Claim reviewed: Sep 30, 2026
    • Published Fact: Healthcare · Claim reviewed: Sep 30, 2026
    • Published Fact: Biotechnology · Claim reviewed: Sep 30, 2026

  2. SEC 20-F 0001213900-26-049412

    sec 20f · Source published: Apr 29, 2026 · Retrieved: Sep 5, 2026

    Supports 13 claims
    • Leadership Role: Dajun Yang, M.D., Ph.D.: Chairman, Chief Executive Officer and Director · Claim reviewed: Sep 30, 2026
    • Leadership Role: Changqing Ye: Director · Claim reviewed: Sep 30, 2026
    • Leadership Role: David Sidransky, M.D.: Director · Claim reviewed: Sep 30, 2026
    • Leadership Role: Debra Yu: Director · Claim reviewed: Sep 30, 2026
    • Leadership Role: Marc E. Lippman, M.D.: Director · Claim reviewed: Sep 30, 2026
    • Leadership Role: Marina S. Bozilenko: Director · Claim reviewed: Sep 30, 2026
    • Leadership Role: Shaomeng Wang, Ph.D.: Director · Claim reviewed: Sep 30, 2026
    • Leadership Role: Simon Dazhong Lu, Ph.D.: Director · Claim reviewed: Sep 30, 2026
    • Leadership Role: Wei Ren: Director · Claim reviewed: Sep 30, 2026
    • Leadership Role: Dajun Yang, M.D., Ph.D.: Chairman, Chief Executive Officer and Director · Claim reviewed: Sep 30, 2026
    • Leadership Role: Thomas J. Knapp: SVP, General Counsel · Claim reviewed: Sep 30, 2026
    • Leadership Role: Veet Misra, Ph.D.: Chief Financial Officer · Claim reviewed: Sep 30, 2026
    • Leadership Role: Yifan Zhai, M.D., Ph.D.: Chief Medical Officer · Claim reviewed: Sep 30, 2026